We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cancer Cells Lack Protein that Blocks Formation of New Blood Vessels

By LabMedica International staff writers
Posted on 18 Jun 2009
Cancer researchers have identified a protein (PHD2) that can slow or prevent tumor growth by inhibiting formation of new blood vessels. More...
However, cancer cells have much lower concentrations of this protein than do neighboring normal tissues.

Investigators from Stanford University (Palo Alto, CA; USA) measured PHD2 levels in samples of human breast and colon cancers and compared them with surrounding tissue. They found that in many cancers the tumors had lower-than-normal levels of PHD2. The investigators then inhibited the expression of PHD2 in a variety of human cancer cells, transplanted those cells into mice with compromised immune systems, and examined the resulting tumors.

Results published in the June 2, 2009, issue of the journal Cancer Cell revealed that tumors arising from cells in which PHD2 expression had been blocked grew more quickly, and were more highly vascularized than the unmodified control cells. Molecular analysis showed that blocking PHD2 expression increased the levels of two proteins involved in blood vessel formation: interleukin-8 (IL-8) and angiogenin.

"Prior to this study it was unclear which of the many proteins involved in vessel growth, or angiogenesis, should be targeted,” said senior author Dr. Amato Giaccia, professor of radiation oncology at Stanford University. "But now we know they play a predominant role in tumor growth. PHD2 appears to be acting as a tumor suppressor by negatively controlling blood vessel formation.”

Related Links:

Stanford University




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.